BiotechTube

Acasunlimab + Pembrolizumab + Docetaxel

Phase 3Active
0 watching 0 views this week📈 Rising
74
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC

Conditions

PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC

Trial Timeline

Nov 25, 2024 → Sep 30, 2028

NCT ID
NCT06635824

About Acasunlimab + Pembrolizumab + Docetaxel

Acasunlimab + Pembrolizumab + Docetaxel is a phase 3 stage product being developed by Genmab for PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC. The current trial status is active. This product is registered under clinical trial identifier NCT06635824. Target conditions include PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC.

Hype Score Breakdown

Clinical
27
Activity
18
Company
7
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT06635824Phase 3Active

Competing Products

2 competing products in PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC

See all competitors
ProductCompanyStageHype Score
MEDI4736AstraZenecaPhase 2
52
MEDI4736 + MEDI4736 + Tremelimumab + Standard of CareAstraZenecaPhase 3
77

Other Products from Genmab

OfatumumabApproved
82
ZalutumumabPhase 3
74
Rina-S + BevacizumabPhase 3
74
Epcoritamab + Cyclophosphamide + Rituximab + Vincristine + Doxorubicin + PrednisonePhase 3
74
Rina-S + Paclitaxel + Topotecan + Pegylated liposomal doxorubicin (PLD) + GemcitabinePhase 3
74